georgie18
4 days ago
MBOT...$1.70...🥳...Been Accumulating...Fins out on March 26,2025... https://www.nasdaq.com/market-activity/stocks/mbot/financials ...Zero Borrow as of 3/21/2025 ...
BRAINTREE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Paul Mullen, a seasoned medical device sales expert in the Endovascular space, to the newly created role of Vice President of Sales. Mr. Mullen has an extensive track record in sales, market development and management, and he will be responsible for leading the Company’s commercial sales in the United States. Mr. Mullen will report directly to Harel Gadot, the Company’s CEO, Chairman and President and his immediate responsibilities include building out the sales strategy and infrastructure to ensure a successful launch upon the FDA clearance. The Company reaffirms its expectation of the FDA decision during the second quarter of 2025.
Mr. Mullen has extensive market experience with medical devices for endovascular diseases, and has successfully launched innovative technologies and driven efficiencies across expansive sales territories. Prior to joining Microbot Medical, Mr. Mullen was Director of Sales at Inari Medical (acquired by Stryker Corporation on February 19, 2025, for $4.94 billion), a provider of medical products designed for the endovascular treatment of deep vein thrombosis (DVT) and pulmonary embolisms (PE). Mr. Mullen was integral in launching multiple breakthrough devices while at Inari, including the first FDA-cleared thrombectomy device for pulmonary embolism. Most recently, he was tasked with launching two new devices to treat chronic venous disease which affects over 1,000,000 patients in the United States. Prior to that he was at Philips Volcano, the endovascular division of the medical company that specializes in image-guided therapy products, where he launched multiple new technologies and generated sales of coronary and peripheral atherectomy product lines. Prior to that, he was the Southeast Regional Sales Manager at LeMaitre Vascular, Inc., a provider of devices for the surgical treatment of peripheral vascular disease, where he managed a team of direct sales representatives focused on vascular surgeons, C-suites and Value Analysis Committees.
georgie18
1 month ago
MBOT...$2.34...🥳...Buying the dips... BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company’s authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about February 11, 2025, subject to the satisfaction of customary closing conditions.
georgie18
1 month ago
MBOT...🥳...$2.85s clearing here...off my $1.80 Range Alert...
georgie18
Member Level
Re: georgie18 post# 1087
Friday, February 07, 2025 10:58:14 AM
Post#
1088
of 1090
MBOT...$2.42 on the Upper Bollie Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 388935
Friday, February 07, 2025 9:56:55 AM
Post#
389830
of 389835
MBOT...$2.36...Trying Upper Bollie Breakout here...🥳
georgie18
Member Level
Re: georgie18 post# 1083
Thursday, January 23, 2025 9:06:33 AM
Post#
1084
of 1086
MBOT...$2.21...🥳
georgie18
Member Level
Re: georgie18 post# 388611
Wednesday, January 22, 2025 10:57:57 AM
Post#
388865
of 388934
MBOT...$2.15 on the Reversal candle...🥳
georgie18
Member Level
Re: georgie18 post# 1080
Thursday, January 16, 2025 7:01:15 AM
Post#
1081
of 1082
MBOT...$1.89...🥳...Been adding dips...from $1.60s to $1.80s
georgie18
2 months ago
MBOT...$2.42 on the Upper Bollie Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 388935
Friday, February 07, 2025 9:56:55 AM
Post#
389830
of 389835
MBOT...$2.36...Trying Upper Bollie Breakout here...🥳
georgie18
Member Level
Re: georgie18 post# 1083
Thursday, January 23, 2025 9:06:33 AM
Post#
1084
of 1086
MBOT...$2.21...🥳
georgie18
Member Level
Re: georgie18 post# 388611
Wednesday, January 22, 2025 10:57:57 AM
Post#
388865
of 388934
MBOT...$2.15 on the Reversal candle...🥳
georgie18
Member Level
Re: georgie18 post# 1080
Thursday, January 16, 2025 7:01:15 AM
Post#
1081
of 1082
MBOT...$1.89...🥳...Been adding dips...from $1.60s to $1.80s
INV4
2 months ago
BREAKING NEWS!
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
https://microbotmedical.com/
===================
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
February 04, 2025 - 8:30AM
BRAINTREE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the acceptance of a late-breaking abstract that will be presented at the upcoming Society of Interventional Radiology (SIR) annual meeting, being held in Nashville, TN on March 29 - April 2, 2025. The data from the Company’s ACCESS-PVI trial, a prospective, multicenter, single-arm trial evaluating the performance and safety of LIBERTY® in patients undergoing peripheral vascular interventions, will be presented for the first time at a podium presentation.
- Abstract/Presentation Title: Remote-controlled endovascular navigation with a miniature, single-use, robotic system. Results of the ACCESS-PVI trial
- Presenter: Francois Cornelis, MD, PhD, FCIRSE, Memorial Sloan Kettering Cancer Center, Department of Radiology.
- Location: Music City Center, Nashville, TN
- Date/Time: Wednesday, April 2, 11:33 AM - 11:42 AM CT
“We believe the acceptance of this late breaking news is critically important and allows the Principal Investigators (PI) to present the data for the first time at the SIR annual meeting, especially since the primary attendees at this conference are potential users of LIBERTY®,” commented Harel Gadot, Chairman, CEO and President. “In addition, we believe that the potential benefits of LIBERTY® will be meaningful and significant to the audience.”
About Microbot Medical®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
$MBOT